Showing 20 of 98 recruiting trials for “squamous-cell-carcinoma-of-the-stomach”
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
👨⚕️ Changqing Pan, the International Committee of Medical Journal Editors📍 1 site📅 Started Sep 2023View details ↗
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
👨⚕️ zhenyu ding, MD, West China Hospital, Sichuan University, China📍 1 site📅 Started Aug 2023View details ↗
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
🏥 Affiliated Cancer Hospital of Shantou University Medical College📍 1 site📅 Started Aug 2023View details ↗
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
👨⚕️ Yu Weiwei, Department of Radiation Oncology, Affiliated Hospital of Nantong University📍 1 site📅 Started Jul 2023View details ↗
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
RecruitingNCT05833594 ↗
Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
RecruitingNCT05894369 ↗
Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
👨⚕️ Feng Wang, phD, The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Mar 2023View details ↗
A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →